176 related articles for article (PubMed ID: 27965050)
1. The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia.
Guo Z; Meng M; Geng S; Du Z; Zheng Y; Yao J; Li Z; Han G; Lin H; Du G
J Ethnopharmacol; 2017 Jan; 196():29-38. PubMed ID: 27965050
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration.
Kim JH; Kim JH; Yu YS; Kim DH; Kim CJ; Kim KW
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1819-23. PubMed ID: 19060284
[TBL] [Abstract][Full Text] [Related]
3. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Lee C; Lin Y; Huang M; Lin C; Liu C; Chow J; Liu HE
Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
[TBL] [Abstract][Full Text] [Related]
4. Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.
Wang X; Zhang X; Xu Z; Wang Z; Yue X; Li H
Biol Pharm Bull; 2013; 36(4):641-8. PubMed ID: 23358330
[TBL] [Abstract][Full Text] [Related]
5. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
Wang R; Liu C; Xia L; Zhao G; Gabrilove J; Waxman S; Jing Y
Clin Cancer Res; 2012 Dec; 18(24):6690-701. PubMed ID: 23082001
[TBL] [Abstract][Full Text] [Related]
6. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
[TBL] [Abstract][Full Text] [Related]
7. MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
Golemovic M; Quintás-Cardama A; Manshouri T; Orsolic N; Duzkale H; Johansen M; Freireich EJ; Kantarjian H; Zingaro RA; Verstovsek S
Invest New Drugs; 2010 Aug; 28(4):402-12. PubMed ID: 19468689
[TBL] [Abstract][Full Text] [Related]
8. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
Chou WC; Dang CV
Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
[TBL] [Abstract][Full Text] [Related]
9. miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines.
Gu J; Zhu X; Li Y; Dong D; Yao J; Lin C; Huang K; Hu H; Fei J
Med Oncol; 2011 Mar; 28(1):211-8. PubMed ID: 20143188
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide preferentially induces nonapoptotic cell deaths as well as actin cytoskeleton rearrangement in the CHO AA8 cell line.
Izdebska M; Klimaszewska-Wiśniewska A; Lewandowski D; Marcin Nowak J; Gagat M; Grzanka A
Postepy Hig Med Dosw (Online); 2014 Dec; 68():1492-500. PubMed ID: 25531713
[TBL] [Abstract][Full Text] [Related]
11. [Effect of Arsenic Trioxide on K562 Cell Proliferation and Its Mechanism].
Wang Y; Yang J; Li J; Wang RC; Yuan J; Li Y; Wang SY; Wang C; Hao HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):90-93. PubMed ID: 28245381
[TBL] [Abstract][Full Text] [Related]
12. Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.
Xia Y; Fang H; Zhang J; Du Y
Exp Biol Med (Maywood); 2013 Aug; 238(8):932-42. PubMed ID: 23883479
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
El Eit R; Itani AR; Nassar F; Rasbieh N; Jabbour M; Santina A; Zaatari G; Mahon FX; Bazarbachi A; Nasr R
Cancer; 2019 Aug; 125(16):2818-2828. PubMed ID: 31034603
[TBL] [Abstract][Full Text] [Related]
15. Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide.
Jang M; Kim Y; Won H; Lim S; K R J; Dashdorj A; Min YH; Kim SY; Shokat KM; Ha J; Kim SS
Cancer Res; 2012 Aug; 72(16):4214-24. PubMed ID: 22719067
[TBL] [Abstract][Full Text] [Related]
16. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C
Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin.
Chiu HW; Ho YS; Wang YJ
J Mol Med (Berl); 2011 Sep; 89(9):927-41. PubMed ID: 21594580
[TBL] [Abstract][Full Text] [Related]
18. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide induces apoptosis and the formation of reactive oxygen species in rat glioma cells.
Sun Y; Wang C; Wang L; Dai Z; Yang K
Cell Mol Biol Lett; 2018; 23():13. PubMed ID: 29610575
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide induces autophagic cell death in osteosarcoma cells via the ROS-TFEB signaling pathway.
Wu B; Tan M; Cai W; Wang B; He P; Zhang X
Biochem Biophys Res Commun; 2018 Jan; 496(1):167-175. PubMed ID: 29307831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
